Table 19.
Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC | NAL | CIP | AZM | COL | SMX | TMP | TET |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Austriaa | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Belgiuma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 0 |
Croatia | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Czech Republic | 50 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 12 | 16 | 0 | 24 | 0 | 0 | 0 |
Francea | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Germanya | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 0 |
Hungarya | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.3 | 33.3 | 0 | 0 | 0 | 0 | 0 |
Poland | 47 | 0 | 2.1 | 4.3 | 0 | 0 | 0 | 0 | 46.8 | 61.7 | 0 | 8.5 | 0 | 0 | 2.1 |
Portugala | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.3 | 0 | 0 | 0 |
Romania | 41 | 0 | 0 | 9.8 | 0 | 0 | 0 | 0 | 4.9 | 14.6 | 0 | 12.2 | 2.4 | 2.4 | 2.4 |
Slovakia | 10 | 0 | 0 | 30 | 0 | 0 | 0 | 0 | 40 | 50 | 0 | 0 | 0 | 0 | 0 |
Spaina | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.3 | 33.3 | 0 | 0 | 0 | 0 | 0 |
Total (12 MSs) | 182 | 0 | 0.5 | 6 | 0 | 0 | 0 | 0 | 19.8 | 27.5 | 0 | 15.4 | 0.5 | 0.5 | 1.1 |
ECOFFs: epidemiological cut‐off values; EUCAST: European Committee on Antimicrobial Susceptibility Testing; N: number of isolates tested; MSs: Member States; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.
The occurrence of resistance is assessed on less than 10 isolates and should only be considered as part of the total from all MSs data.